Tim Oldham is the CEO & MD of AdAlta, ASX code 1AD. Tim has more than 15 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products. He joined me to chat about AD-214 the drug that AdAlta is developing for the treatment of pulmonary fibrosis.

The company and/or guest has contributed to the costs associated with producing this episode of The Equity Investor Journey.

IMPORTANT – Please remember these podcasts are produced to provide information and education and they are not designed to provide financial advice nor are they a recommendation to buy shares in the companies featured. ASA does not endorse or favour any specific commercial product or company. Please obtain independent professional advice before investing.

We value your feedback and questions. Please contact us at [email protected] if you have any suggestions for guests or specific questions you’d like answered.

Hosted on Acast. See acast.com/privacy for more information.